Stcube announces interim results from Phase 2 trial in non-small cell lung cancer… 73% patient enrollment
Predicted impact: Medium
Phase 2 interim results for lung cancer drug; material for a ₩471B company.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.